Table 2 Pharmacotherapy
Incident hypo 12 months FU Median (quartiles) or % (n=473) | No hypo 12 months FU Median (quartiles) or % (n=2874) | p-value / OR (95%CI) | |
|---|---|---|---|
Any OAD monotherapy | 14.4 | 15.6 | 0.91 (0.69-1.20) |
Metformin | 9.5 | 8.7 | 1.11 (0.80-1.55) |
Sulfonylureas | 1.3 | 1.9 | 0.66 (0.28-1.54) |
Glucosidaseinhibitors | 0.0 | 0.2 | -- |
Glinides | 1.3 | 0.7 | 1.75 (0.70-4.36) |
Glitazones | 0.4 | 0.5 | 0.94 (0.21-4.16) |
DPP-4 inhibitors | 1.9 | 3.6 | 0.52 (0.26-1.03) |
Injectable monotherapy | 11.0 | 2.8 | 4.32 (3.01-6.22) |
GLP-1 analogues only | 0.0 | 0.9 | -- |
Insulin only | 11.0 | 1.8 | 6.59 (4.43-9.79) |
Dual oral combination therapy | 33.1 | 52.9 | 0.44 (0.36-0.54) |
Met + SU | 13.8 | 12.5 | 1.12 (0.84-1.49) |
Met + Glucosidaseinhibitors | 0.2 | 1.3 | 0.17 (0.02-1.22) |
Met + Glinides | 2.1 | 2.2 | 0.95 (0.48-1.86) |
Met + Glitazones | 2.5 | 5.4 | 0.46 (0.28-0.83) |
Met + DPP-4 inhibitors | 12.3 | 29.3 | 0.34 (0.25-0.45) |
SU + Glitazones | 0.4 | 0.3 | 1.22 (0.27-5.58) |
SU + DPP-4 inhibitors | 0.8 | 1.3 | 0.67 (0.24-1.90) |
OAD + GLP-1 analogues | 4.4 | 9.0 | 0.47 (0.30-0.74) |
OAD + Insulin | 31.8 | 11.3 | 3.65 (2.92-4.58) |
Other combinations | 5.3 | 8.4 | -- |